scholarly article | Q13442814 |
P356 | DOI | 10.1159/000151367 |
P698 | PubMed publication ID | 18714168 |
P50 | author | Quanhai Li | Q39369637 |
P2093 | author name string | Fangzhou Song | |
Youquan Bu | |||
Zhengmei Yang | |||
P433 | issue | 3-4 | |
P921 | main subject | esophageal cancer | Q372701 |
P304 | page(s) | 198-206 | |
P577 | publication date | 2008-08-20 | |
P1433 | published in | Oncology | Q2016300 |
P1476 | title | Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells | |
P478 | volume | 74 |
Q38598778 | Association of ECRG4 with PLK1, CDK4, PLOD1 and PLOD2 in esophageal squamous cell carcinoma |
Q30496149 | Cancer biomarker discovery: the entropic hallmark |
Q28076060 | Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications |
Q36071638 | Current progress of siRNA/shRNA therapeutics in clinical trials |
Q47132417 | Decreased KPNB1 Expression is Induced by PLK1 Inhibition and Leads to Apoptosis in Lung Adenocarcinoma |
Q90291164 | Elimination of HER3-expressing breast cancer cells using aptamer-siRNA chimeras |
Q57359344 | Enhancing Gene-Knockdown Efficiency of Poly(-isopropylacrylamide) Nanogels |
Q28278655 | Growth inhibition, morphology change, and cell cycle alterations in NFBD1-depleted human esophageal cancer cells |
Q90396711 | Identification of PLK1 as a New Therapeutic Target in Mucinous Ovarian Carcinoma |
Q39141522 | Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells |
Q92177878 | Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications |
Q42748194 | MEK inhibition induces apoptosis in osteosarcoma cells with constitutive ERK1/2 phosphorylation. |
Q39830221 | Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma |
Q37335160 | Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients |
Q28078772 | PLK1, A Potential Target for Cancer Therapy |
Q33829178 | Polo-like kinase 1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass |
Q36105529 | Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma |
Q33662727 | RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma |
Q38966322 | RNAi-mediated silencing of the Skp-2 gene causes inhibition of growth and induction of apoptosis in human renal carcinoma cells |
Q35216353 | SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis |
Q47147377 | SUMOylation regulates the localization and activity of Polo-like kinase 1 during cell cycle in the silkworm, Bombyx mori. |
Q41927888 | Sequential Cdk1 and Plk1 phosphorylation of protein tyrosine phosphatase 1B promotes mitotic cell death. |
Q33514778 | Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas |
Q33564389 | Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells |
Q37386185 | The expression of PLK-1 in cervical carcinoma: a possible target for enhancing chemosensitivity |
Q28548580 | Translational Nano-Medicines: Targeted Therapeutic Delivery for Cancer and Inflammatory Diseases |
Search more.